CBDX — Curative Biosciences Share Price
Last trade - 00:00- $0.00m
- $0.16m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2013 | 2014 | 2015 | 2016 | 2017 | 2018E | 2019E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.16 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Curative Biosciences, Inc., formerly Amaize Beverage Corporation, is a life sciences company focused on developing and commercializing novel therapeutics using hemp-derived CBD (hemp derived Cannabidiol). The Company’s product segment is focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. The Company through its consumer products business manufactures market and sells consumer products containing plant-based CBD under the brand Curative Biosciences.
Directors
- Last Annual
- June 30th, 2017
- Last Interim
- March 31st, 2018
- Incorporated
- August 4th, 2000
- Public Since
- August 26th, 2004
- No. of Employees
- 220
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 31,574,695
- Address
- 1111 Brickell Ave., 11Th Floor, MIAMI, 33131
- Web
- http://curativebiosciences.com/
- Phone
- +1 5619356449
- Auditors
- Haynie & Co.
Similar to CBDX
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 20:07 UTC, shares in Curative Biosciences are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Curative Biosciences last closed at $0.00 and the price had moved by -93.33% over the past 365 days. In terms of relative price strength the Curative Biosciences share price has underperformed the S&P500 Index by -93.77% over the past year.
There is no consensus recommendation for this security.
Find out moreCurative Biosciences does not currently pay a dividend.
Curative Biosciences does not currently pay a dividend.
Curative Biosciences does not currently pay a dividend.
To buy shares in Curative Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Curative Biosciences had a market capitalisation of $0.00m.
Here are the trading details for Curative Biosciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CBDX
Based on an overall assessment of its quality, value and momentum Curative Biosciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Curative Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +3.51%.
As of the last closing price of $0.00, shares in Curative Biosciences were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Curative Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Curative Biosciences' management team is headed by:
- Katherine West - CHM
- A. Grandsaert - PRE
- Richard Damion - CEO
- William Lindberg - CFO